Xenon Submits NDA for Azetukalner in Focal Seizures Amid Psychiatry Trial Pause
Event summary
- Xenon Pharmaceuticals submitted an NDA for azetukalner in focal seizures to the FDA, based on positive Phase 2b and Phase 3 trial data.
- The company voluntarily paused enrollment in psychiatry studies (MDD and BPD) due to neuropsychiatric adverse events, though current patients remain in trials.
- X-NOVA2 study in MDD completed enrollment with ~360 patients; topline data expected Q1 2027.
- Ongoing Phase 3 epilepsy studies (X-TOLE3 and X-ACKT) continue enrolling patients for expanded use.
The big picture
Xenon's NDA submission marks a critical step toward its goal of becoming a fully integrated neuroscience company. The voluntary pause in psychiatry trials highlights the challenges of balancing innovation with patient safety, particularly in complex indications like MDD and BPD. The epilepsy market remains underserved, with up to half of focal epilepsy patients living with uncontrolled seizures, creating a significant opportunity for azetukalner if approved.
What we're watching
- Regulatory Timeline
- The pace at which the FDA reviews the azetukalner NDA will determine Xenon's path to commercialization in epilepsy.
- Psychiatry Program Risk
- Whether dosing modifications can mitigate neuropsychiatric adverse events in MDD and BPD trials will shape future psychiatry development.
- Market Differentiation
- How azetukalner's differentiated mechanism of action and once-daily dosing position it against existing antiseizure medications.